References
 Mol Neurobiol 2020 Jun; Vol. 57 (6), pp. 2654-2670
<a href="https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19596275" target="_blank" rel="noopener noreferrer">Brain Res. 2009 Sep 22; 1290: 1–11. </a>
JAMA.2003;289(20):2651-2662. 

--- 

Support this podcast: <a href="https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support" rel="payment">https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support</a>

BioMedical Portraits I. Chapter 7. Hormone replacement and the general distinctions of cholesterol homeostasis, metabolic zonation, hydroxysterols and estrogen receptor heterogeneity in female AD.

Become a Paid Subscriber: https://anchor.fm/dr-daniel-j-guerra/subscribe


Become a Paid Subscriber: https://anchor.fm/dr-daniel-j-guerra/subscribe

You have wisely landed upon Authentic Biochemistry, with Dr. Daniel J Guerra, where published biochemical, physiological, genetic and immunological research along with biomedical and pharmaceutical science are interrogated.

Anchor (from Spotify)

Authentic Biochemistry

Biomedical Portraits I. Part 5. 17-beta estradiol monotherapy in post-menopausal women has no irrefutable therapeutic benefit for treating cognitive decline in early AD dementia.DJGPhD.8AUG23.AB.

BioMedical Portraits I. Chapter 6. Complications of female cerebrovascular trauma and obesity-linked Type2 Diabetes in post-menopausal estrogen therapeutics for prophylactic treatment of subsequent AD